Rhabdomyolysis during high dose interleukin-2 treatment of metastatic melanoma after sequential immunotherapies: a case report
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2051-1426
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Rhabdomyolysis during high dose interleukin-2 treatment of metastatic melanoma after sequential immunotherapies: a case report ; volume:6 ; number:1 ; day:14 ; month:6 ; year:2018 ; pages:1-5 ; date:12.2018
Journal for ImmunoTherapy of Cancer ; 6, Heft 1 (14.6.2018), 1-5, 12.2018
- Urheber
-
Clark, Joseph I.
- Beteiligte Personen und Organisationen
-
Bufalino, Shams
Singh, Shruti
Borys, Ewa
SpringerLink (Online service)
- DOI
-
10.1186/s40425-018-0370-6
- URN
-
urn:nbn:de:101:1-2018082219085225640868
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:25 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Clark, Joseph I.
- Bufalino, Shams
- Singh, Shruti
- Borys, Ewa
- SpringerLink (Online service)
Ähnliche Objekte (12)
Combining talimogene laherparepvec with immunotherapies in melanoma and other solid tumors
Towards the generation of novel natural killer cell-based immunotherapies against melanoma
Towards the Generation of novel Natural Killer Cell-based Immunotherapies against Melanoma
Omeprazole-associated rhabdomyolysis
Talimogene laherparepvec (T-VEC) and Emerging Intralesional Immunotherapies for Metastatic Melanoma: A Review
Interleukin 32 expression in human melanoma
Rhabdomyolysis induced by nelarabine
Perspectives on Exertional Rhabdomyolysis
Immunotherapies in solid tumors
Immunotherapies in rare cancers
Rhabdomyolysis in drug-related deaths
Pazopanib and Statin-Induced Rhabdomyolysis
Combining talimogene laherparepvec with immunotherapies in melanoma and other solid tumors
Towards the generation of novel natural killer cell-based immunotherapies against melanoma
Towards the Generation of novel Natural Killer Cell-based Immunotherapies against Melanoma
Omeprazole-associated rhabdomyolysis
Talimogene laherparepvec (T-VEC) and Emerging Intralesional Immunotherapies for Metastatic Melanoma: A Review
Interleukin 32 expression in human melanoma
Rhabdomyolysis induced by nelarabine
Perspectives on Exertional Rhabdomyolysis
Immunotherapies in solid tumors
Immunotherapies in rare cancers
Rhabdomyolysis in drug-related deaths
Pazopanib and Statin-Induced Rhabdomyolysis
Combining talimogene laherparepvec with immunotherapies in melanoma and other solid tumors
Towards the generation of novel natural killer cell-based immunotherapies against melanoma
Towards the Generation of novel Natural Killer Cell-based Immunotherapies against Melanoma
Omeprazole-associated rhabdomyolysis
Talimogene laherparepvec (T-VEC) and Emerging Intralesional Immunotherapies for Metastatic Melanoma: A Review
Interleukin 32 expression in human melanoma
Rhabdomyolysis induced by nelarabine
Perspectives on Exertional Rhabdomyolysis
Immunotherapies in solid tumors
Immunotherapies in rare cancers
Rhabdomyolysis in drug-related deaths